Keymed Biosciences, Inc. (HK:2162) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Keymed Biosciences Inc. has announced that China’s National Medical Products Administration approved its drug Stapokibart for treating chronic rhinosinusitis with nasal polyposis. The phase III clinical trial showed significant improvements in nasal polyp size and congestion, with a favorable safety profile. This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.